

Table I-21
US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2005^a
USING DIFFERENT TUMOR INCLUSION CRITERIA^b

| Site/Sex | 5-Year Limited Duration | | | 30-year Limited Duration | |
|-----------------------|--------------------------------------|--|---|--------------------------------------|--|
| | 1st Invasive Tumor Ever ^c | 1st Per Site in Previous 30 Years ^d | 1st Per Site in Previous 5 Years ^e | 1st Invasive Tumor Ever ^c | 1st Per Site in Previous 30 Years ^d |
| All Sites | 4,047,630 | 4,124,002 | 4,471,606 | 10,505,741 | 10,700,724 |
| Male | 2,069,338 | 2,097,658 | 2,265,792 | 4,896,353 | 4,954,654 |
| Female | 1,978,292 | 2,026,344 | 2,205,814 | 5,609,388 | 5,746,070 |
| Oral Cavity & Pharynx | 86,675 | 99,393 | 102,699 | 223,620 | 245,611 |
| Male | 58,447 | 66,437 | 68,409 | 144,387 | 157,204 |
| Female | 28,228 | 32,956 | 34,290 | 79,233 | 88,407 |
| Esophagus | 18,953 | 22,591 | 22,591 | 27,187 | 31,941 |
| Male | 14,462 | 17,126 | 17,126 | 20,510 | 23,821 |
| Female | 4,491 | 5,465 | 5,465 | 6,677 | 8,120 |
| Stomach | 31,518 | 37,554 | 37,666 | 60,885 | 69,650 |
| Male | 18,834 | 22,619 | 22,647 | 34,789 | 40,033 |
| Female | 12,684 | 14,935 | 15,019 | 26,096 | 29,617 |
| Colon & Rectum | 414,431 | 477,379 | 485,167 | 1,050,283 | 1,168,268 |
| Male | 209,554 | 241,797 | 245,238 | 515,575 | 570,013 |
| Female | 204,877 | 235,582 | 239,929 | 534,708 | 598,255 |
| Liver & Intrahep | 15,981 | 18,086 | 18,086 | 21,259 | 23,745 |
| Male | 11,073 | 12,473 | 12,473 | 14,023 | 15,605 |
| Female | 4,908 | 5,613 | 5,613 | 7,236 | 8,140 |
| Pancreas | 21,905 | 26,051 | 26,051 | 29,026 | 33,751 |
| Male | 10,950 | 13,152 | 13,152 | 14,178 | 16,577 |
| Female | 10,955 | 12,899 | 12,899 | 14,848 | 17,174 |
| Larynx | 30,668 | 35,999 | 36,272 | 88,989 | 98,327 |
| Male | 24,542 | 28,792 | 29,019 | 71,335 | 78,509 |
| Female | 6,126 | 7,207 | 7,253 | 17,654 | 19,818 |
| Lung & Bronchus | 206,013 | 255,746 | 260,876 | 348,273 | 417,553 |
| Male | 99,962 | 125,160 | 127,386 | 165,661 | 198,810 |
| Female | 106,051 | 130,586 | 133,490 | 182,612 | 218,743 |
| Melanoma of the Skin | 221,975 | 247,168 | 256,223 | 677,773 | 725,006 |
| Male | 116,685 | 132,017 | 137,768 | 333,977 | 360,601 |
| Female | 105,290 | 115,151 | 118,455 | 343,796 | 364,405 |
| Breast | | | | | |
| Female | 808,737 | 867,285 | 909,008 | 2,377,471 | 2,521,460 |
| Cervix | | | | | |
| Female | 40,655 | 42,514 | 42,620 | 189,952 | 195,487 |
| Corpus & Uterus | | | | | |
| Female | 145,463 | 163,808 | 163,843 | 511,115 | 554,123 |
| Ovary ^f | | | | | |
| Female | 53,959 | 63,067 | 63,111 | 151,232 | 170,276 |

^a US 2005 cancer prevalence counts are based on 2005 cancer prevalence proportions from the SEER 9 registries and 1/1/2005 US population estimates based on the average of 2004 and 2005 population estimates from the US Bureau of the Census.

^{bcd} (b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 30 years (1975-2004); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2000-2004). For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2000; Melanoma in 2001.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 30-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2005.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 30-year limited duration prevalence. The 2000 breast cancer is counted for the breast 5-year and 30-year limited duration prevalence.

In method (e) the 2000 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2001 melanoma is counted for 5-year limited duration prevalence for melanoma.

^f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table I-21 - continued
US PREVALENCE COUNTS, INVASIVE CANCERS ONLY, JANUARY 1, 2005^a
USING DIFFERENT TUMOR INCLUSION CRITERIA^b

| Site/Sex | 5-Year Limited Duration | | | 30-year Limited Duration | |
|------------------------|--------------------------------------|--|---|--------------------------------------|--|
| | 1st Invasive Tumor Ever ^c | 1st Per Site in Previous 30 Years ^d | 1st Per Site in Previous 5 Years ^e | 1st Invasive Tumor Ever ^c | 1st Per Site in Previous 30 Years ^d |
| Prostate | | | | | |
| Male | 939,384 | 1,013,473 | 1,013,521 | 2,102,958 | 2,244,449 |
| Testis | | | | | |
| Male | 39,561 | 40,196 | 40,664 | 165,843 | 167,969 |
| Urinary Bladder | | | | | |
| Male | 187,611 | 229,342 | 232,628 | 500,529 | 575,400 |
| Female | 140,466 | 171,744 | 174,234 | 370,894 | 424,832 |
| Female | 47,145 | 57,598 | 58,394 | 129,635 | 150,568 |
| Kidney & Renal Pelvis | | | | | |
| Male | 105,967 | 127,975 | 128,978 | 242,021 | 279,591 |
| Female | 63,208 | 77,412 | 78,092 | 142,504 | 165,759 |
| Female | 42,759 | 50,563 | 50,886 | 99,517 | 113,832 |
| Brain & Nervous System | | | | | |
| Male | 40,067 | 41,895 | 42,078 | 105,744 | 108,660 |
| Female | 21,582 | 22,580 | 22,690 | 56,701 | 58,150 |
| Female | 18,485 | 19,315 | 19,388 | 49,043 | 50,510 |
| Thyroid | | | | | |
| Male | 111,720 | 120,840 | 121,123 | 344,182 | 362,308 |
| Female | 24,952 | 28,074 | 28,096 | 76,616 | 81,765 |
| Female | 86,768 | 92,766 | 93,027 | 267,566 | 280,543 |
| Hodgkin Lymphoma | | | | | |
| Male | 34,567 | 36,114 | 36,138 | 140,716 | 143,814 |
| Female | 18,082 | 18,848 | 18,859 | 72,571 | 74,112 |
| Female | 16,485 | 17,266 | 17,279 | 68,145 | 69,702 |
| Non-Hodgkin Lymphoma | | | | | |
| Male | 173,017 | 198,936 | 200,239 | 389,438 | 430,711 |
| Female | 89,995 | 104,311 | 104,889 | 201,376 | 222,211 |
| Female | 83,022 | 94,625 | 95,350 | 188,062 | 208,500 |
| Myeloma | | | | | |
| Male | 37,951 | 43,567 | 43,601 | 55,888 | 63,084 |
| Female | 20,764 | 24,306 | 24,340 | 30,945 | 35,402 |
| Female | 17,187 | 19,261 | 19,261 | 24,943 | 27,682 |
| Leukemia | | | | | |
| Male | 91,507 | 103,055 | 103,168 | 213,808 | 231,461 |
| Female | 52,959 | 59,875 | 59,932 | 120,855 | 131,096 |
| Female | 38,548 | 43,180 | 43,236 | 92,953 | 100,365 |
| Acute Lymphocytic Leuk | | | | | |
| Male | 14,454 | 14,746 | 14,746 | 52,633 | 53,040 |
| Female | 8,169 | 8,268 | 8,268 | 28,919 | 29,056 |
| Female | 6,285 | 6,478 | 6,478 | 23,714 | 23,984 |
| Childhood (0-19) | | | | | |
| Male | 59,044 | 59,122 | 59,392 | 248,912 | 249,391 |
| Female | 31,593 | 31,637 | 31,734 | 127,804 | 128,005 |
| Female | 27,451 | 27,485 | 27,658 | 121,108 | 121,386 |
| Kaposi Sarcoma | | | | | |
| Male | 6,456 | 6,920 | 6,920 | 20,669 | 21,698 |
| Female | 5,958 | 6,317 | 6,317 | 19,259 | 20,131 |
| Female | 498 | 603 | 603 | 1,410 | 1,567 |
| Mesothelioma | | | | | |
| Male | 2,847 | 3,600 | 3,600 | 4,361 | 5,219 |
| Female | 2,040 | 2,599 | 2,599 | 2,646 | 3,276 |
| Female | 807 | 1,001 | 1,001 | 1,715 | 1,943 |

^a US 2005 cancer prevalence counts are based on 2005 cancer prevalence proportions from the SEER 9 registries and 1/1/2005 US population estimates based on the average of 2004 and 2005 population estimates from the US Bureau of the Census.

^{bcde} (b) Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion: (c) First invasive tumor ever; (d) First invasive tumor for each cancer site diagnosed during the previous 30 years (1975-2004); (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2000-2004). For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2000; Melanoma in 2001.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 30-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2005.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 30-year limited duration prevalence. The 2000 breast cancer is counted for the breast 5-year and 30-year limited duration prevalence.

In method (e) the 2000 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2001 melanoma is counted for 5-year limited duration prevalence for melanoma.